Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 69 clinical trials
Peri-operative SLOG for Localized Pancreatic Cancer

To evaluate the efficacy of neoadjuvant chemotherapy SLOG in localized pancreatic cancer To evaluate the safety profile in patients with pancreatic cancer who receive neoadjuvant SLOG To collect tumor tissue and peripheral blood samples from the patients for a comprehensive biomarker evaluation

resectable pancreatic cancer
cancer chemotherapy
leucovorin
gemcitabine
measurable disease
  • 0 views
  • 26 Sep, 2021
  • 3 locations
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

This phase II trial evaluates whether early switching from modified fluorouracil/irinotecan/leucovorin/oxaliplatin (mFOLFIRINOX) chemotherapy regimen to a combination of gemcitabine and nab-paclitaxel (GA) before surgery is effective in treating patients with pancreatic cancer that can be surgically removed (resectable or borderline resectable), or that has spread to nearby tissue or lymph …

  • 0 views
  • 22 Mar, 2022
  • 1 location
Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer

This pilot and feasibility study studies how well nivolumab and combination chemotherapy work before surgery in treating patients with pancreatic cancer that could possibly be removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body?s immune system attack the cancer, and may interfere with the ability …

  • 0 views
  • 23 May, 2022
  • 1 location
Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma

Relapses free survival will be evaluated as efficacy of carbon ions radiation therapy released before surgery.

adenocarcinoma
metastasis
cancer chemotherapy
pancreatic neoplasm
karnofsky performance status
  • 0 views
  • 12 Sep, 2021
  • 1 location
SBRT and Anti-programmed Cell Death Protein 1(Anti-PD-1) in Late Stage or Recurrent Pancreatic Cancer Patients (CISPD-2)

When gemcitabine based chemo and fluorouracil based chemo regimes are failed in late-stage or recurrent pancreatic cancer patients, there is no alternative options. Anti-PD-1 antibody has became a promising anti-cancer drug. While it showed limited efficacy in pancreatic cancer. Stereotactic Body Radiotherapy has been a new method to locally treat …

cancer chemotherapy
metastasis
gemcitabine
antineoplastic
stereotactic body radiation therapy
  • 37 views
  • 15 Feb, 2022
  • 1 location
Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma

The purpose of this study is to determine if neoadjuvant therapy to increases resection rate for pancreatic adenocarcinoma.

  • 0 views
  • 29 Mar, 2021
  • 1 location
Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer

This is an open-label, phase 2 study of Pembrolizumab in combination with chemotherapy in chemotherapy-nave advanced pancreatic cancer

  • 0 views
  • 27 Mar, 2021
  • 1 location
Radiotherapy for Locally Advanced Pancreatic Carcinomas (Phase II Trial) (LAPC)

This is an interventional, single-arm, open-label study with high dose short course radiotherapy for patients with locally advanced pancreatic cancer.

metastasis
cancer chemotherapy
celiac
  • 0 views
  • 25 Apr, 2022
  • 1 location
Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies

Phase 1 Safety and Tolerability Study in Subjects with Pancreatic Cancer or Other CA19-9 Positive Malignancies.

ca19-9
adenocarcinoma
pancreatic ductal adenocarcinoma
breast ductal carcinoma
measurable disease
  • 10 views
  • 09 Aug, 2022
  • 4 locations
Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)

This is a prospective, randomized phase II trial. The aim of this study is to assess the efficacy of two therapeutics strategies. Patients with borderline-resectable pancreatic cancer (BRPC) will be randomly in two arms : neoadjuvant mFolfirinox followed with or without preoperative chemoradiotherapy with capecitabine.

chemoradiotherapy
adenocarcinoma
capecitabine
cancer chemotherapy
gemcitabine
  • 28 views
  • 26 Apr, 2022
  • 24 locations